CEN BIOTECH INC (CENBF) financial statements (2022 and earlier)

Company profile

Business Address 300-3295 QUALITY WAY
WINDSOR, ON N8T 3R9
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 24385623
Cash and cash equivalents 24385623
Receivables 18     
Total current assets: 204385623
Noncurrent Assets
Operating lease, right-of-use asset  229
Property, plant and equipment  14816715168,292
Long-term investments and receivables 1,2241,1104545  
Due from related parties 1,2241,1104545  
Intangible assets, net (including goodwill) 4,9565,3815,8066,2312,320 
Intangible assets, net (excluding goodwill) 4,9565,3815,8066,2312,320 
Deferred costs    217  
Other undisclosed noncurrent assets 114   1,695 
Total noncurrent assets: 6,2946,8696,0176,5074,0328,292
Other undisclosed assets  4241,2942,429  
TOTAL ASSETS: 6,3147,2967,3159,0214,0948,295
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1,95710,3417,4694,9293,7151,986
Accounts payable 19118120793157165
Accrued liabilities 641575402296841594
Interest and dividends payable 1,1259,5856,8604,5412,7171,228
Debt 7,70715,30713,70511,44419,9259,866
Due to related parties 1,3721,3631,361126375
Other undisclosed current liabilities 3,6703,8581,8733,642(9,009)1,564
Total current liabilities: 14,70630,86824,40820,02714,69413,491
Noncurrent Liabilities
Long-term debt and lease obligation 2201,2231,5462,2081,392 
Long-term debt, excluding current maturities 781,0391,5462,2081,392 
Operating lease, liability 142184
Liabilities, other than long-term debt    300  
Due to related parties    300  
Other undisclosed noncurrent liabilities 1,2385562,6225,5001,388612
Total noncurrent liabilities: 1,6001,9634,1688,0082,780612
Total liabilities: 16,30632,83228,57628,03617,47414,103
Stockholders' equity
Stockholders' equity attributable to parent, including: (9,992)(25,535)(21,261)(19,015)(13,390)(5,808)
Preferred stock     00
Common stock     00
Additional paid in capital 17,06915,77514,3949,11010 
Accumulated deficit (27,061)(41,310)(35,655)(28,125)(13,390)(5,808)
Other undisclosed stockholders' equity attributable to parent     (10) 
Other undisclosed stockholders' equity     10 
Total stockholders' equity: (9,992)(25,535)(21,261)(19,015)(13,380)(5,808)
TOTAL LIABILITIES AND EQUITY: 6,3147,2967,3159,0214,0948,295

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues     2 
Gross profit:     2 
Operating expenses (2,544)(2,580)(4,371)(11,614)(5,981)(1,166)
Other undisclosed operating loss     (2) 
Operating loss: (2,544)(2,580)(4,371)(11,614)(5,981)(1,166)
Nonoperating income (expense) 16,793(3,075)(3,160)(2,466)(1,601)(121)
Foreign currency transaction gain (loss), before tax (55)(66)92(89)(48)(121)
Interest and debt expense (443)(450)(431)(336)(288)(1,362)
Net income (loss): 13,806(6,105)(7,961)(14,417)(7,870)(2,649)
Other undisclosed net income attributable to parent 443450431336288242
Net income (loss) available to common stockholders, basic: 14,250(5,655)(7,530)(14,080)(7,582)(2,407)
Dilutive securities, effect on basic earnings per share 585     
Net income (loss) available to common stockholders, diluted: 14,835(5,655)(7,530)(14,080)(7,582)(2,407)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss): 13,806(6,105)(7,961)(14,417)(7,870)(2,649)
Comprehensive income (loss), net of tax, attributable to parent: 13,806(6,105)(7,961)(14,417)(7,870)(2,649)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: